Brought to you by 
Cephalon pays $100mm up front for option to buy Ception
23 Feb 2010
Executive Summary
Cephalon has paid $100mm up front for an option to purchase all of the outstanding stock of privately held Ception Therapeutics (treatments for inflammatory and allergic diseases).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon pays $100mm up front for option to buy Ception
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice